Roche taps Horizon for NTRK cancer assay support

Roche is due to receive the finished materials within 12 months.

Roche has tasked Horizon Discovery with developing reference standard material that expresses NTRK fusion biomarkers. The agreement supports Roche’s drive to develop immunohistochemistry (IHC) assays that enable doctors to identify patients with NTRK gene rearrangements.

Cambridge, U.K.-based Horizon will apply its gene editing platform to the task. Using the platform, Horizon plans to develop cell lines that include knock-ins of NTRK 1,2 and 3 fusion cDNA. These will each be controlled by multiple promoters. Horizon will supply the cell lines in the formalin-fixed paraffin embedded format, a method it thinks controls variability by mimicking patient samples. 

Roche is due to receive the finished materials within 12 months. 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Interest in IHC tests capable of identifying patients with NTRK gene rearrangements has increased in line with data on the effect of TRK inhibitors in certain cancer patients. These drugs, notably Loxo Oncology’s larotrectinib, have wowed with data linking them to objective responses in most patients. 

Roche has a specific interest in the field.

RELATED: Roche strikes cancer companion diagnostic deal with Loxo

Nine months ago, Roche’s Ventana Medical Systems signed up to develop a pan-TRK companion diagnostic for Loxo’s larotrectinib. That deal put Roche in charge of further developing an IHC test Loxo had already advanced part way to optimization and validation. Roche’s role is to finish the job using its OptiView DAB detection technology. 

In turning to Horizon for support, Roche has built upon a relationship it entered into last year. The original deal also leveraged Horizon’s cell line capabilities to support the development of IHC cancer assays.

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its "Star Trek"-inspired digital X-ray bed.